Effects of four angiotensin II-receptor antagonists on fibrinolysis in postmenopausal women with hypertension

被引:17
作者
Fogari, R [1 ]
Zoppi, A [1 ]
Malamani, G [1 ]
Marasi, G [1 ]
Pesce, RM [1 ]
Banderali, A [1 ]
Mugellini, A [1 ]
机构
[1] Univ Pavia, Policlin San Matteo, IRCCS, Dept Internal Med & Therapeut,Clin Med, I-27100 Pavia, Italy
来源
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL | 2001年 / 62卷 / 01期
关键词
fibrinolysis; angiotensin II antagonist; hypertension;
D O I
10.1016/S0011-393X(01)80043-6
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Reduced fibrinolysis due to increased concentrations of plasminogen activator inhibitor type 1 (PAI-1), the primary physiological inhibitor of endogenous fibrinolysis, is associated with an increased risk for cardiovascular events. Objective: This study was undertaken to compare the effects of 4 angiotensin II (AII)-receptor antagonists with different pharmacokinetic properties-losartan, valsartan, irbesartan, and candesartan-on levels of PAI-1 antigen in postmenopausal women with hypertension. Methods: Postmenopausal women aged 51 to 60 years with mild to moderate hypertension (diastolic blood pressure [DBP] >90 mm Hg and less than or equal to 105 mm Hg) who were not taking any hormone replacement therapy were studied. Patients with diabetes or obesity and patients who smoked were excluded. After a 2-week placebo washout period, patients were assigned to receive losartan 50 mg, valsartan 80 mg, irbesartan 150 mg, candesartan 8 mg, or placebo for 12 weeks according to a double-blind, randomized, parallel-group design, with a titration for nonresponders after 6 weeks. At the end of the placebo period and 6 and 12 weeks after active treatment, blood pressure, PAI-1 antigen levels, heart rate, and body mass index were measured. Results: A total of 156 patients were randomized to receive losartan (n = 31), valsartan (n = 32), irbesartan (n = 31), candesartan (n = 32), or placebo (n = 30); of these, 140 completed the study. All 4 active treatments significantly reduced DBP and systolic blood pressure, with no significant differences in efficacy between groups. Plasma PAI-1 levels decreased slightly after treatment with losartan (-0.9%) and valsartan (-3.8%) and increased slightly with irbesartan (+10.1%), but these values were not significantly different from placebo. In contrast, candesartan significantly increased PAI-1 values by 33.3% (P < 0.05 vs placebo). There were no significant changes in heart rate or body mass index in any group. Conclusions: These findings suggest that, despite a comparable antihypertensive efficacy, candesartan differs from the other All-receptor antagonists studied in that it significantly increases PAI-1 antigen levels. This might be related to its specific pharmacologic characteristics, particularly its insurmountable antagonism of the All AT1 receptor.
引用
收藏
页码:68 / 78
页数:11
相关论文
共 39 条
[31]   ASSOCIATION OF FIBRINOLYTIC PARAMETERS WITH EARLY ATHEROSCLEROSIS - THE ARIC STUDY [J].
SALOMAA, V ;
STINSON, V ;
KARK, JD ;
FOLSOM, AR ;
DAVIS, CE ;
WU, KK .
CIRCULATION, 1995, 91 (02) :284-290
[32]   Effect of angiotensin II receptor blockade on fibrinolysis during acute hyperinsulinemia in patients with essential hypertension [J].
Seljeflot, I ;
Moan, A ;
Kjeldsen, S ;
Sandvik, E ;
Arnesen, H .
HYPERTENSION, 1996, 27 (06) :1299-1304
[33]   HEMOSTATIC FACTORS AND THE RISK OF MYOCARDIAL-INFARCTION OR SUDDEN-DEATH IN PATIENTS WITH ANGINA-PECTORIS [J].
THOMPSON, SG ;
KIENAST, J ;
PYKE, SDM ;
HAVERKATE, F ;
VANDELOO, JCW .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (10) :635-641
[34]   Relationship between endothelial function and fibrinolysis in early hypertension [J].
Tomiyama, H ;
Kimura, Y ;
Mitsuhashi, H ;
Kinouchi, T ;
Yoshida, H ;
Kushiro, T ;
Doba, N .
HYPERTENSION, 1998, 31 (01) :321-327
[35]   ANGIOTENSIN-II INCREASES PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 AND TISSUE-TYPE PLASMINOGEN-ACTIVATOR MESSENGER-RNA IN CULTURED RAT AORTIC SMOOTH-MUSCLE CELLS [J].
VANLEEUWEN, RTJ ;
KOL, A ;
ANDREOTTI, F ;
KLUFT, C ;
MASERI, A ;
SPERTI, G .
CIRCULATION, 1994, 90 (01) :362-368
[36]  
Vaughan DE, 1997, CIRCULATION, V96, P442
[37]   ANGIOTENSIN-II REGULATES THE EXPRESSION OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 IN CULTURED ENDOTHELIAL-CELLS - A POTENTIAL LINK BETWEEN THE RENIN-ANGIOTENSIN SYSTEM AND THROMBOSIS [J].
VAUGHAN, DE ;
LAZOS, SA ;
TONG, K .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (03) :995-1001
[38]   EFFECTS OF CAPTOPRIL THERAPY ON ENDOGENOUS FIBRINOLYSIS IN MEN WITH RECENT, UNCOMPLICATED MYOCARDIAL-INFARCTION [J].
WRIGHT, RA ;
FLAPAN, AD ;
ALBERTI, KGMM ;
LUDLAM, CA ;
FOX, KAA .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1994, 24 (01) :67-73
[39]   EFFECT OF ENALAPRIL ON MYOCARDIAL-INFARCTION AND UNSTABLE ANGINA IN PATIENTS WITH LOW EJECTION FRACTIONS [J].
YUSUF, S ;
PEPINE, CJ ;
GARCES, C ;
POULEUR, H ;
SALEM, D ;
KOSTIS, J ;
BENEDICT, C ;
ROUSSEAU, M ;
BOURASSA, M ;
PITT, B .
LANCET, 1992, 340 (8829) :1173-1178